Metabolic Dysfunction-Associated Steatohepatitis Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036

Metabolic Dysfunction-Associated Steatohepatitis Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036

Report Format: PDF+Excel | Report ID: SR112026A28014

1    Preface

2    Scope and Methodology
    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology

3    Executive Summary

4    Metabolic Dysfunction-Associated Steatohepatitis - Introduction
    4.1 Overview
    4.2 Regulatory Process
    4.3 Epidemiology (​2020-2025​) and Forecast (​2026-2036​)
    4.4 Market Overview (​2020-2025​) and Forecast (​2026-2036​)
    4.5 Competitive Intelligence

5 Metabolic Dysfunction-Associated Steatohepatitis - Disease Overview
    5.1    Introduction
    5.2    Symptoms and Diagnosis
    5.3    Pathophysiology
    5.4    Causes and Risk Factors
    5.5    Treatment

6 Patient Journey

7 Metabolic Dysfunction-Associated Steatohepatitis - Epidemiology and Patient Population
    7.1    Epidemiology - Key Insights    
    7.2    Epidemiology Scenario - Top 7 Markets

            7.2.1 Epidemiology Scenario (​2020-2025​)        
            7.2.2 Epidemiology Forecast (​2026-2036​)    
            7.2.3 Epidemiology by Age (​2020-2036​)
            7.2.4 Epidemiology by Gender (​2020-2036​)    
            7.2.5 Diagnosed Cases (​2020-2036​)
            7.2.6 Patient Pool/Treated Cases (​2020-2036​)        
    7.3    Epidemiology Scenario - United States    
             7.3.1 Epidemiology Scenario (​2020-2025​)    
             7.3.2 Epidemiology Forecast (​2026-2036​)    
             7.3.3 Epidemiology by Age (​2020-2036​)    
             7.3.4 Epidemiology by Gender (​2020-2036​)
             7.3.5 Diagnosed Cases (​2020-2036​)
             7.3.6 Patient Pool/Treated Cases (​2020-2036​)    
    7.4    Epidemiology Scenario - Germany    
             7.4.1 Epidemiology Scenario (​2020-2025​)    
             7.4.2 Epidemiology Forecast (​2026-2036​)    
             7.4.3 Epidemiology by Age (​2020-2036​)
             7.4.4 Epidemiology by Gender (​2020-2036​)
             7.4.5 Diagnosed Cases (​2020-2036​)
             7.4.6 Patient Pool/Treated Cases (​2020-2036​)
    7.5    Epidemiology Scenario - France    
             7.5.1 Epidemiology Scenario (​2020-2025​)
             7.5.2 Epidemiology Forecast (​2026-2036​)
             7.5.3 Epidemiology by Age (​2020-2036​)
             7.5.4 Epidemiology by Gender (​2020-2036​)
             7.5.5 Diagnosed Cases (​2020-2036​)
             7.5.6 Patient Pool/Treated Cases (​2020-2036​)
     7.6    Epidemiology Scenario - United Kingdom
             7.6.1 Epidemiology Scenario (​2020-2025​)    
             7.6.2 Epidemiology Forecast (​2026-2036​)    
             7.6.3 Epidemiology by Age (​2020-2036​)    
             7.6.4 Epidemiology by Gender (​2020-2036​)    
             7.6.5 Diagnosed Cases (​2020-2036​)
             7.6.6 Patient Pool/Treated Cases (​2020-2036​)    
    7.7    Epidemiology Scenario - Italy    
          7.7.1 Epidemiology Scenario (​2020-2025​)    
          7.7.2 Epidemiology Forecast (​2026-2036​)    
          7.7.3 Epidemiology by Age (​2020-2036​)    
          7.7.4 Epidemiology by Gender (​2020-2036​)    
          7.7.5 Diagnosed Cases (​2020-2036​)
          7.7.6 Patient Pool/Treated Cases (​2020-2036​)
    7.8    Epidemiology Scenario - Spain    
          7.8.1 Epidemiology Scenario (​2020-2025​)    
          7.8.2 Epidemiology Forecast (​2026-2036​)    
          7.8.3 Epidemiology by Age (​2020-2036​)    
          7.8.4 Epidemiology by Gender (​2020-2036​)    
          7.8.5 Diagnosed Cases (​2020-2036​)
          7.8.6 Patient Pool/Treated Cases (​2020-2036​)
    7.9    Epidemiology Scenario - Japan    
         7.9.1 Epidemiology Scenario (​2020-2025​)    
         7.9.2 Epidemiology Forecast (​2026-2036​)    
         7.9.3 Epidemiology by Age (​2020-2036​)
         7.9.4 Epidemiology by Gender (​2020-2036​)
         7.9.5 Diagnosed Cases (​2020-2036​)
         7.9.6 Patient Pool/Treated Cases (​2020-2036​)

8 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Treatment Algorithm, Guidelines, and Medical Practices
    8.1    Guidelines, Management and Treatment
    8.2    Treatment Algorithm    

9   Metabolic Dysfunction-Associated Steatohepatitis Treatment - Unmet Needs    

10 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Key Endpoints of Treatment

11 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Marketed Products        
11.1 List of Metabolic Dysfunction-Associated Steatohepatitis Treatment - Marketed Drugs Across the Top 7 Markets    
         11.1.1 Rezdiffra (Resmetirom) - Madrigal Pharmaceuticals

            11.1.1.1 Drug Overview    
            11.1.1.2 Mechanism of Action    
            11.1.1.3 Clinical Trial Results    
            11.1.1.4 Safety and Efficacy
            11.1.1.5 Regulatory Status

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Pipeline Products    
12.1 List of Metabolic Dysfunction-Associated Steatohepatitis Treatment Pipeline Drugs Across the Top 7 Markets
12.1.1 Pegozafermin – 89bio

               12.1.1.1 Drug Overview    
               12.1.1.2 Mechanism of Action    
               12.1.1.3 Clinical Trial Results    
               12.1.1.4 Safety and Efficacy
               12.1.1.5 Regulatory Status
12.1.2 Efruxifermin – Akero Therapeutics
               12.1.2.1 Drug Overview
               12.1.2.2 Mechanism of Action
               12.1.2.3 Clinical Trial Results
               12.1.2.4 Safety and Efficacy  
               12.1.2.5 Regulatory Status 
12.1.3 Miricorilant – Corcept Therapeutics
               12.1.3.1 Drug Overview
               12.1.3.2 Mechanism of Action
               12.1.3.3 Clinical Trial Results
               12.1.3.4 Safety and Efficacy                
               12.1.3.5 Regulatory Status  
12.1.4 ALG-055009 – Aligos Therapeutics
               12.1.4.1 Drug Overview
               12.1.4.2 Mechanism of Action
               12.1.4.3 Clinical Trial Results
               12.1.4.4 Safety and Efficacy                
               12.1.4.5 Regulatory Status  
12.1.5 ALN-HSD – Regeneron Pharmaceuticals
               12.1.5.1 Drug Overview
               12.1.5.2 Mechanism of Action
               12.1.5.3 Clinical Trial Results
               12.1.5.4 Safety and Efficacy                
               12.1.5.5 Regulatory Status 

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Attribute Analysis of Key Marketed and Pipeline Drugs    

14 Metabolic Dysfunction-Associated Steatohepatitis Treatment – Clinical Trial Landscape
    14.1 Drugs by Status
    14.2 Drugs by Phase
    14.3 Drugs by Route of Administration    
    14.4 Key Regulatory Events

15 Metabolic Dysfunction-Associated Steatohepatitis Treatment Market Scenario    
    15.1    Market Scenario - Key Insights    
    15.2    Market Scenario - Top 7 Markets
 
         15.2.1 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Market Size             
                  15.2.1.1 Market Size (​2020-2025​)    
                  15.2.1.2 Market Forecast (​2026-2036​)
         15.2.2 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Market Size by Therapies
                  15.2.2.1 Market Size by Therapies (​2020-2025​)
                  15.2.2.2 Market Forecast by Therapies (​2026-2036​)    
  15.3    Market Scenario - United States    
        15.3.1 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Market Size
              15.3.1.1 Market Size (​2020-2025​)    
                15.3.1.2 Market Forecast (​2026-2036​)
        15.3.2 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Market Size by Therapies
                 15.3.2.1 Market Size by Therapies (​2020-2025​)
                15.3.2.2 Market Forecast by Therapies (​2026-2036​)
      15.3.3 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Access and Reimbursement Overview
15.4    Market Scenario - Germany    
           15.4.1 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Market Size
                  15.4.1.1 Market Size (​2020-2025​)        
                  15.4.1.2 Market Forecast (​2026-2036​)    
     15.4.2 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Market Size by Therapies    
15.4.2.1 Market Size by Therapies (​2020-2025​)    
                 15.4.2.2 Market Forecast by Therapies (​2026-2036​)
        15.4.3 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Access and Reimbursement Overview
15.5    Market Scenario - France    
        15.5.1 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Market Size    
                 15.5.1.1 Market Size (​2020-2025​)    
                 15.5.1.2 Market Forecast (​2026-2036​)    
     15.5.2 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Market Size by Therapies    
                 15.5.2.1 Market Size by Therapies (​2020-2025​)    
                 15.5.2.2 Market Forecast by Therapies (​2026-2036​)
        15.5.3 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Access and Reimbursement Overview 
15.6    Market Scenario – United Kingdom
        15.6.1 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Market Size    
                  15.6.1.1 Market Size (​2020-2025​)    
                 15.6.1.2 Market Forecast (​2026-2036​)
         15.6.2 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Market Size by Therapies
                 15.6.2.1 Market Size by Therapies (​2020-2025​)
          15.6.2.2 Market Forecast by Therapies (​2026-2036​)
     15.6.3 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Access and Reimbursement Overview
15.7    Market Scenario – Italy
            15.7.1 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Market Size    
                 15.7.1.1 Market Size (​2020-2025​)    
         15.7.1.2 Market Forecast (​2026-2036​)
          15.7.2 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Market Size by Therapies
                 15.7.2.1 Market Size by Therapies (​2020-2025​)
                  15.7.2.2 Market Forecast by Therapies (​2026-2036​)
          15.7.3 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Access and Reimbursement Overview 
15.8    Market Scenario - Spain
            15.8.1 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Market Size    
                 15.8.1.1 Market Size (​2020-2025​)
         15.8.1.2 Market Forecast (​2026-2036​)    
         15.8.2 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Market Size by Therapies
                 15.8.2.1 Market Size by Therapies (​2020-2025​)    
                 15.8.2.2 Market Forecast by Therapies (​2026-2036​)
     15.8.3 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Access and Reimbursement Overview
 15.9    Market Scenario - Japan    
            15.9.1 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Market Size    
          15.9.1.1 Market Size (​2020-2025​)    
                 15.9.1.2 Market Forecast (​2026-2036​)    
      15.9.2 Metabolic Dysfunction-Associated Steatohepatitis Treatment- Market Size by Therapies 
                  15.9.2.1 Market Size by Therapies (​2020-2025​)
                  15.9.2.2 Market Forecast by Therapies (​2026-2036​)
         15.9.3 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Access and Reimbursement Overview

16 Metabolic Dysfunction-Associated Steatohepatitis Treatment - Recent Events and Inputs From Key Opinion Leaders

17 Metabolic Dysfunction-Associated Steatohepatitis Treatment Market - SWOT Analysis    
   17.1    Strengths    
   17.2    Weaknesses    
   17.3    Opportunities    
   17.4    Threats         

18 Metabolic Dysfunction-Associated Steatohepatitis Treatment – Strategic Recommendation

19 Appendix

Metabolic Dysfunction-Associated Steatohepatitis Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036
Purchase Options Discount
Offer
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-201-971-6302

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials